At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 24 enrolled
Drug / intervention
68Ga-grazytracerdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
68Ga-grazytracer PET/CT of Tumor Responses to Immunotherapy in Subjects with Solid Tumor or Lymphoma
Peking University Cancer Hospital & Institute·interventional·Posted Aug 11, 2021·Updated Dec 4, 2024
In Brief
A Phase 2 clinical trial evaluating 68Ga-grazytracer for Cancer. Completed, enrolled 24 participants across 1 site.
Detailed Summary
This is an open-label positron emission tomography/computed tomography (PET/CT) study to investigate the safety and clinical predictive value of 68Ga-grazytracer in subjects with solid tumor or lymphoma receiving immunotherapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCancer
CountriesChina
CollaboratorsPeking University Health Science Center
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedAug 2021
Enrollment StartSep 2021
Primary CompletionMay 2024
Study CompletionMay 2024
TodayJul 2026
First PostedAug 11, 2021
Enrollment StartSep 22, 2021
Primary CompletionMay 25, 2024
Study CompletionMay 31, 2024
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 4.9 years ago
Interventions
68Ga-grazytracerdrug
68Ga-grazytracer PET/CT: after intravenous injection of 2.96-3.7 MBq/kg body weight of quality-controlled 68Ga-grazytracer, a Biograph mCT Flow 64 scanner or Total-body PET/CT uEXPLORER scanner will be applied, and the scan range will be from the top of the head to 1/3 of the upper thigh.